SAN DIEGO, CA – October 15, 2024 – Antharis Therapeutics, a pioneering biopharmaceutical company advancing breakthrough immunotherapeutic treatments in oncology, is pleased to announce that Daniel Yazbeck has joined the company as Head of Corporate Strategy. Mr. Yazbeck brings over two decades of expertise in strategic operations, product development, and business expansion within the healthcare and biotechnology sectors. In his role at Antharis, Mr. Yazbeck will lead high-impact strategic initiatives and provide counsel to CEO and Chairman, Dr. Raphael Ribeiro-Pinaud, on critical corporate development efforts as the company continues to grow and advance its portfolio of transformative cancer biotherapies.
“We are thrilled to welcome Daniel to the Antharis team,” said Dr. Ribeiro-Pinaud. “His proven record in building successful teams, launching innovative healthcare solutions, and forming strategic partnerships makes him an invaluable addition to our executive group as we drive Antharis’ mission and objectives forward. Daniel’s experience and vision align with our commitment to bringing life-changing therapies to patients in need, and I am confident he will play a crucial role in successfully advancing our corporate strategy and long-term goals.”
With a career foundation as a scientist at Pfizer Pharmaceuticals, where he co-founded Pfizer’s Biocatalysis group, Mr. Yazbeck’s work has spanned across scientific innovation, healthcare product development, and corporate leadership. During his tenure at Panasonic, Mr. Yazbeck led business development for healthcare-focused divisions and later founded MyDx, a diagnostics company that he founded and took to the public market. His multidisciplinary background and entrepreneurial spirit have consistently driven his success in building and executing strategies that deliver value and impact.
“I am excited to join Antharis at such a pivotal time,” said Mr. Yazbeck. “Antharis is at the forefront of immunotherapeutic innovation, with a commitment to developing transformative treatments that make a real difference in the lives of patients suffering from devastating diseases. I look forward to working alongside with Raphael and contributing to the Antharis team to accelerate the company’s strategic goals and realize its full potential as a leader in oncology.”
Mr. Yazbeck earned his Bachelor’s degree in Biochemistry and Marketing and his Master’s degree in Medicinal Chemistry from McGill University in Canada. Prior to joining Antharis, he was a private investor and the founder of Yazbeck & Co., an investment firm focused on identifying and leveraging transformative healthcare solutions.
About Antharis Therapetuics
Antharis Therapeutics is a leading biopharmaceutical company focused on developing innovative monoclonal antibody therapies for oncology and other critical medical fields. The company’s unique approach to cancer treatment leverages the power of immuno-oncology, enhancing the body’s immune response to fight cancer. With a robust pipeline of therapies and a multidisciplinary team of experts, Antharis is dedicated to transforming the future of healthcare by delivering safe, effective, and life-changing treatments to patients worldwide. For more information, please visit www.antharistherapeutics.com.
